ATG-fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: A prospective randomized pilot trial

Annals of Transplantation

Volumn 13, Issue 4, 2008, Pages 21-27

  Kim, Min Jeong ^a   Tsinalis, Dimitrios ^a   Franz, Stefan ^a   Binet, Isabelle ^a   Gürke, Lorenz ^a   Mihatsch, Michael J ^a   Steiger, Jürg ^a   Thiel, Gilbert ^a   Dickenmann, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anti IL 2 R antibody; Anti T lymphocyte immunoglobulin; Induction therapy; Sensitized renal transplant Recipients

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ABDOMINAL ABSCESS; ABDOMINAL WALL HERNIA; ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLADDER LEAKAGE; BLEEDING; BLOOD GROUP TYPING; BRONCHITIS; CHOLANGITIS; CHOLECYSTIC POLYP; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART INFARCTION; HERPES SIMPLEX; HERPES ZOSTER RADICULITIS; HIGH RISK PATIENT; HOSPITALIZATION COST; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; ISCHEMIC COLITIS; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; URETER OBSTRUCTION; URINARY TRACT INFECTION; UROSEPSIS; VIRAL GASTROENTERITIS; WOUND HEALING IMPAIRMENT; BLOOD; CADAVER; CHRONIC KIDNEY FAILURE; DONOR; IMMUNOLOGY; LIVING DONOR; MORTALITY; PHYSIOLOGY; RISK FACTOR; SAFETY; SURVIVAL; SURVIVOR;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CADAVER; CREATININE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS; SAFETY; SURVIVAL ANALYSIS; SURVIVORS; TISSUE DONORS; YOUNG ADULT;

EID: 65849346789     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Flechner SM: Current status of renal transplantation. Urol Clin North Amer, 1994: 21: 265
2. Racusen LC, Solez K, Colvin RB et al: The Banff 97 working classification of renal allograft pathology. Kidney International, 1999: 55: 713
3. Charpentier B, Thervet E: Placebo-Controlled Study of a Humanized Anti-TAC Monoclonal Antibody in Dual Therapy for Prevention of Acute Rejection After Renal Transplantation. Transplant Proc, 1998: 30: 1331
4. Nashan B, Moore R, Amlot P et al: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet, 1997: 350: 1193
5. Vincenti F, Kirkman R, Light S et al: Interleukin- 2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med, 1998: 338: 161
6. Kaden J, May G, Schoenemann C et al: Effect of ATG Prophylaxis in sensitized and non-sensitized kidney graft recipients. Transplant Int, 1992: 5(Suppl.1): 75
7. Vela C, Cristol JP, Chong G et al: Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients. Transplant Int, 1994: 7(Suppl.1): 259
8. Thibaudin D, Alamartine E, De Filippis JP et al: Advantage of antithymocyte induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant, 1998: 13: 711
9. Akalin E, Ames S, Sehgal V et al: Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation, 2003: 76: 1444
10. Sollinger H, Kaplan B, Pescovitz MD et al: Basiliximab versus Antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation, 2001: 72: 1915
11. Martins L, Henriques AC, Dias L et al: Anti- Interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results. Transplant Proc, 2000: 32: 2623
12. Lebranchu Y, Bridoux F, Bühler M et al: Immunoprophylaxis with Basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant, 2002: 2: 48
13. Brennan DC, Daller JA, Lake KD et al: Rabbit antithymocyte globulin versus Basiliximab in renal transplantation. N Engl J Med, 2006: 355: 1967
14. Guyatt GH, Mills EJ, Elbourne D: In the era of systematic reviews, does the size of an individual trial still matter? PloS Med, 2008: 5(1): e4